Chris Wealth Management

Search This Blog

Is Anthem Biosciences IPO a risky bet for investors?

Posted by Able on July 13, 2025

Get link
Facebook
X
Pinterest
Email
Other Apps

Anthem Biosciences, a contract research, development, and manufacturing organisation (CRDMO), aims to raise ₹3,395 crore through an offer for sale. Post-IPO, the promoter group's stake is set to decline from 76.9% to 74.7%.

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Stock Market LIVE Updates: Hong Kong stocks notch 9-day winning streak in longest rally since 2018

Hong Kong stocks extended their rally on Friday, supported by ongoing positive market sentiment fueled by China's increased economic stimulus measures. The Hang Seng Index surged by 1.5%, marking its ninth consecutive day of gains, the longest winning streak since January 2018. Hong Kong-listed Chinese tech giants also saw continued gains, closing 2.7% higher.

Jiraaf launches India’s first Bond Analyser to decode fixed-income investing

Jiraaf launches Bond Analyser to simplify bond investing for retail investors. Tool compares yields by rating, tenure, and issuer using public data. Aims to close the research gap in India’s growing fixed-income market. Future updates may include scenario modeling and structured debt analysis.

NSE cautions investors against entity offering guaranteed returns

The National Stock Exchange (NSE) on Friday cautioned investors against an entity offering guaranteed returns on investment in the stock market. The statement came after the exchange noticed that an authorised person of its registered stock broker was offering guaranteed returns and was collecting commission on such assured returns from investors.

Is Anthem Biosciences IPO a risky bet for investors?

Comments

Post a Comment